- Home
- NIVF vs QNTM Comparison
NIVF vs QNTM Comparison
Compare NIVF & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- QNTM
- Stock Information
- Founded
- NIVF 2011
- QNTM 1998
- Country
- NIVF Thailand
- QNTM Canada
- Employees
- NIVF N/A
- QNTM N/A
- Industry
- NIVF
- QNTM
- Sector
- NIVF
- QNTM
- Exchange
- NIVF NYSE
- QNTM NYSE
- Market Cap
- NIVF 9.2M
- QNTM 9.1M
- IPO Year
- NIVF N/A
- QNTM N/A
- Fundamental
- Price
- NIVF $0.53
- QNTM $5.01
- Analyst Decision
- NIVF
- QNTM
- Analyst Count
- NIVF 0
- QNTM 0
- Target Price
- NIVF N/A
- QNTM N/A
- AVG Volume (30 Days)
- NIVF 2.5M
- QNTM 66.2K
- Earning Date
- NIVF 11-29-2024
- QNTM 11-12-2024
- Dividend Yield
- NIVF N/A
- QNTM N/A
- EPS Growth
- NIVF N/A
- QNTM N/A
- EPS
- NIVF 0.21
- QNTM N/A
- Revenue
- NIVF $5,136,153.00
- QNTM N/A
- Revenue This Year
- NIVF N/A
- QNTM N/A
- Revenue Next Year
- NIVF N/A
- QNTM N/A
- P/E Ratio
- NIVF $2.81
- QNTM N/A
- Revenue Growth
- NIVF N/A
- QNTM N/A
- 52 Week Low
- NIVF $0.47
- QNTM $3.50
- 52 Week High
- NIVF $17.24
- QNTM $96.20
- Technical
- Relative Strength Index (RSI)
- NIVF 37.54
- QNTM 49.79
- Support Level
- NIVF $0.50
- QNTM $4.75
- Resistance Level
- NIVF $0.67
- QNTM $5.17
- Average True Range (ATR)
- NIVF 0.11
- QNTM 0.42
- MACD
- NIVF -0.02
- QNTM -0.03
- Stochastic Oscillator
- NIVF 12.27
- QNTM 32.42
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.